πŸ‡ΊπŸ‡Έ FDA
Patent

US 11696922

Nanoparticle to target cancer

granted A61KA61K31/7088A61K31/713

Quick answer

US patent 11696922 (Nanoparticle to target cancer) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jul 11 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 06 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K31/7088, A61K31/713, A61K47/10, A61K47/183